Comparing radiation plus cetuximab to radiation plus chemotherapy in people with advanced head and neck cancer who cannot receive cisplatin.
Currently Available for Patients
About This Study
NRG-HN016, also known as the “CONCISE” study, is a clinical trial comparing two usual approaches for people who have advanced head and neck cancer and are unable to take the chemotherapy drug cisplatin. Typically, patients with this type of cancer are treated with radiation therapy combined with either chemotherapy, such as carboplatin and paclitaxel, or an anti-cancer drug such as cetuximab. For patients who receive the usual approach, about 35 out of 100 are free of cancer after 2 years. The NRG-HN016 trial will be comparing both of these usual treatments for your type of cancer.
This study will help the study doctors find out if the usual approach of radiation and chemotherapy is better, the same, or worse than the usual approach radiation and cetuximab. To decide if it is better, the study doctors will be looking to see if the radiation and chemotherapy approach will increase the number of patients without their disease getting worse after 2 years from about 63 out of 100 with radiation and cetuximab, to 73 out of 100 with radiation and chemotherapy.
More information about this particular study is located on ClinicalTrials.gov
Am I eligible for this study?
People who have advanced head and neck cancer that are not able to receive the chemotherapy drug cisplatin may be eligible for the study. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take this information to your doctor to discuss your questions and concerns in general and specific to the NRG-HN016 study.
Are there other studies for which I might be eligible?
Please talk to your healthcare team to see if there are other clinical studies for which you may be a good fit. Click here if you would like to view a more detailed chart of other studies available.
Find a Study Location
Are you interested in joining the study? Find a participating location
Want more information?
Additional information for the NRG-HN016 study can be found in the Patient Study Brochure. Download Brochure

Frequently Asked Questions
Below, you can find FAQs about clinical research and this particular clinical trial.
The NRG-HN016 Study FAQ
Who is this study for?
Who is this study for?
People who have advanced head and neck cancer and are unable to receive one of the standard chemotherapy treatments called cisplatin.
Why is this study being done?
Why is this study being done?
This study is being done to answer the following question: Does the usual approach of radiation therapy plus the chemotherapy drugs carboplatin and paclitaxel extend the time without your cancer getting worse compared to the usual approach of radiation therapy and cetuximab?
What are the possible treatments?
What are the possible treatments?
If you decide to take part in this study, you will either get the usual radiation therapy plus cetuximab for 8 weeks, or you will get the usual radiation therapy plus carboplatin and paclitaxel chemotherapy for 7 weeks.
What is the usual approach for my type of cancer?
What is the usual approach for my type of cancer?
The usual approach for patients who are unable to receive cisplatin and who are not in a study is treatment with radiation therapy combined with either chemotherapy, such as carboplatin and paclitaxel, or an anti-cancer drug such as cetuximab. Cetuximab is an antibody that specifically targets cancer cells. There are several other targeted therapy drugs and other chemotherapy drugs approved by the Food and Drug Administration (FDA) that are commonly used with the radiation therapy. For patients who get the usual approach for this cancer, about 35 out of 100 are free of cancer after 2 years.
What are some possible risks I might experience from taking part in this study?
What are some possible risks I might experience from taking part in this study?
If you choose to take part in this study, there is a risk that the usual approach of radiation plus chemotherapy may not be as good as the usual approach of radiation plus cetuximab at shrinking or stabilizing your cancer. There is also a risk that you could have side effects from the chemotherapy or cetuximab. These side effects may be worse and may be different than you would get with the usual approach for your cancer. There may be some risks that the study doctors do not yet know about.
What are some possible benefits I can expect from taking part in this study?
What are some possible benefits I can expect from taking part in this study?
There is evidence that both study drug therapies, chemotherapy or cetuximab, plus radiation are effective in shrinking or stabilizing your type of cancer. It is not possible to know now if the radiation plus chemotherapy approach will extend your time without disease getting worse compared to the radiation plus cetuximab approach. This study will help the study doctors learn things that will help people in the future.
How long will I be in this study?
How long will I be in this study?
After you finish your treatment, your doctor and study team will continue to follow your condition and watch you for side effects. They will check you at 4 months, 6 months, and then every 6 months up until year 3 after you finish treatment. After that, they will continue to follow your condition annually for your lifetime.
Am I required to be in this study?
Am I required to be in this study?
No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.
What are the costs of participating on this study?
What are the costs of participating on this study?
You and/or your insurance plan will need to pay for the costs of medical care you get as part of the study, just as you would if you were getting the usual care for your cancer.
This includes:
- the costs of tests, exams, procedures, and drugs that you get during the study to monitor your safety, and prevent and treat side effects.
- the cetuximab (if you are in Group 1) or chemotherapy (if you are in Group 2), including the costs of getting it ready and giving it to you.
- the radiation therapy
- your insurance co-pays and deductibles.
Talk to your insurance provider and make sure that you understand what your insurance pays for and what it doesn’t pay for if you take part in this clinical trial. Also, find out if you need approval from your plan before you can take part in the study.
You will not be paid for taking part in this study.
Who has access to my information?
Who has access to my information?
Your privacy is very important to us and the researchers will make every effort to protect it. Your information may be given out if required by law. For example, certain states require doctors to report to health boards if they find a disease like tuberculosis. However, the researchers will do their best to make sure that any information that is released will not identify you. Some of your health information and/or information about your specimens from this study will be kept in a central database for research. Your name or contact information will not be put in the database.
There are organizations that may inspect your records. These organizations are required to make sure your information is kept private, unless required by law to provide information. Some of these organizations are:
- The study sponsor, NRG Oncology.
- The National Cancer Institute (NCI) Central Investigational Review Board (IRB), which is a group of people who review the research with the goal of protecting the people who take part in the study.
- The Food & Drug Administration (FDA) and the groups it works with to review research.
- The NCI and the groups it works with to review research, including the Cancer Trials Support Unit (CTSU).
- The NCI’s National Clinical Trials Network and the groups it works with to conduct research including the Imaging and Radiation Oncology Core (IROC).
Clinical Studies FAQ
What is a clinical study?
What is a clinical study?
Doctors and researchers conduct a clinical study, also called a “clinical trial,” to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute (NCI) and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see “Types of Clinical Trials” and “Phases of Clinical Trials”.
Patients who volunteer to take part in a clinical study are followed closely by their health care professionals and members of the research team. For more information see “Research Team Members”.
Is a clinical study the same thing as a clinical trial?
Is a clinical study the same thing as a clinical trial?
Yes. They are exactly the same thing.
Why are clinical studies important?
Why are clinical studies important?
The care cancer doctors provide to cancer patients today is the direct result of clinical studies (also known as clinical trials) that were done in the past. Clinical studies give doctors and the treatment team information about what types of treatments work and what treatments do not work, in a number of different situations. Some studies focus on treating the cancer, others on preventing the cancer, and others on helping patients feel better or healthier during or after treatments. When you take part in a clinical study, you add to our knowledge about cancer and it may help improve cancer care for future patients. Clinical studies are available to patients with many types of cancer and at all stages of treatment. In some situations, the only way to get these new treatments is by joining a clinical study.
Where and how are clinical studies conducted?
Where and how are clinical studies conducted?
A clinical study may take place in many locations, such as:
A study is typically led by a principal investigator who is a doctor or other advanced health care professional. A clinical study is carried out by following a very specific plan known as the “protocol”. The protocol is designed so all patients in the study are treated as well as possible and in the same way. The protocol also provides rules for the doctors and clinical study staff to follow to keep patients safe and make sure the study is run in an ethical manner.
Am I required to participate in a clinical study?
Am I required to participate in a clinical study?
No, not at all. Participation in a clinical study is completely voluntary. For more information see “Deciding to Take Part in a Clinical Trial”. You are free to choose to participate or not to participate. If you choose to participate in a study, you may still decide to leave the study at any time. If you decide not to participate in a study, your doctor will discuss other treatment options with you. For more information see “Questions to Ask Your Doctor about Treatment Clinical Trials“.
What are my other choices if I do not take part in this study?
What are my other choices if I do not take part in this study?
- You may choose to have the usual treatment approach (known as “standard of care”)
- You may choose to take part or learn more about a different study, if one is available
- You may choose not to be treated for cancer
About NRG Oncology
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trial’s Network.